After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution ...

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

Revolution Medicines announced a stunning survival benefit for its experimental drug in a Phase 3 pancreatic cancer study ...

Kala is building the Palantir for biotech, just as Palantir built a $250+ billion company by helping governments and enterprises make sense of massive data, Kala is doing the same for the biotech and ...

CRISPR-Cas9 technology has revolutionized biotechnology by providing an efficient, precise, and versatile tool for genome editing. This RNA-guided system allows scientists to target specific DNA ...

Discover how Anneo Biotech is quietly leading India's probiotic revolution, building the future of preventive healthcare.

Ahmedabad: While the state is often termed the ‘pharmacy of India' due to a mature ecosystem of pharmaceuticals in terms of ...

ARLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) announces that it is ready to ship its first commercial AI product in approximately 14 days, transforming the Company ...